Four Finalists Vie for $100 Mil. Aventis Drug

NEW YORK — Four finalists are making presentations this week in a review for Lantus, a diabetes drug from Aventis Pharmaceuticals, sources said.

Billings on the global account, which includes both creative and media duties, have not been determined. Sources, however, pegged them at $100 million.

The presentations are taking place on Monday and Tuesday at the client’s U.S. headquarters in Bridgewater, N.J. The finalists are Interpublic Group’s McCann-Erickson, Omnicom Group’s TBWA Worldwide, Havas’ Euro RSCG and the WPP Group team of Young & Rubicam, Burson-Marsteller and Mediaedge:cia, said sources.